191 related articles for article (PubMed ID: 37079136)
1. Longitudinal changes in serum adropin levels and liver fat content during liraglutide treatment in newly diagnosed patients with type 2 diabetes mellitus and metabolic dysfunction-associated fatty liver disease.
Zhang L; Wu X; Li X; Chang X; Ding X; Wang Q; Jiang T; Wang G; Liu J
Acta Diabetol; 2023 Jul; 60(7):971-979. PubMed ID: 37079136
[TBL] [Abstract][Full Text] [Related]
2. Liraglutide Decreases Liver Fat Content and Serum Fibroblast Growth Factor 21 Levels in Newly Diagnosed Overweight Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease.
Li X; Wu X; Jia Y; Fu J; Zhang L; Jiang T; Liu J; Wang G
J Diabetes Res; 2021; 2021():3715026. PubMed ID: 34660809
[TBL] [Abstract][Full Text] [Related]
3. Serum Adropin as a Potential Biomarker for Predicting the Development of Type 2 Diabetes Mellitus in Individuals With Metabolic Dysfunction-Associated Fatty Liver Disease.
Li N; Xie G; Zhou B; Qu A; Meng H; Liu J; Wang G
Front Physiol; 2021; 12():696163. PubMed ID: 34366886
[No Abstract] [Full Text] [Related]
4. Effect of liraglutide therapy on serum fetuin A in patients with type 2 diabetes and non-alcoholic fatty liver disease.
Zhang LY; Qu XN; Sun ZY; Zhang Y
Clin Res Hepatol Gastroenterol; 2020 Oct; 44(5):674-680. PubMed ID: 32113823
[TBL] [Abstract][Full Text] [Related]
5. Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease.
Yan J; Yao B; Kuang H; Yang X; Huang Q; Hong T; Li Y; Dou J; Yang W; Qin G; Yuan H; Xiao X; Luo S; Shan Z; Deng H; Tan Y; Xu F; Xu W; Zeng L; Kang Z; Weng J
Hepatology; 2019 Jun; 69(6):2414-2426. PubMed ID: 30341767
[TBL] [Abstract][Full Text] [Related]
6. Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial).
Kuchay MS; Krishan S; Mishra SK; Choudhary NS; Singh MK; Wasir JS; Kaur P; Gill HK; Bano T; Farooqui KJ; Mithal A
Diabetologia; 2020 Nov; 63(11):2434-2445. PubMed ID: 32865597
[TBL] [Abstract][Full Text] [Related]
7. Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease.
Feng W; Gao C; Bi Y; Wu M; Li P; Shen S; Chen W; Yin T; Zhu D
J Diabetes; 2017 Aug; 9(8):800-809. PubMed ID: 28332301
[TBL] [Abstract][Full Text] [Related]
8. ADROPIN - POTENTIAL LINK IN CARDIOVASCULAR PROTECTION FOR OBESE MALE TYPE 2 DIABETES MELLITUS PATIENTS TREATED WITH LIRAGLUTIDE.
Tičinović Kurir T; Miličević T; Novak A; Vilović M; Božić J
Acta Clin Croat; 2020 Jun; 59(2):344-350. PubMed ID: 33456123
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic Effects and Mechanism of Liraglutide in Rats with Type 2 Diabetes and Metabolic-associated Fatty Liver Disease.
Zhao X; Liu Y; Liu J; Qin J
Endocr Metab Immune Disord Drug Targets; 2022; 22(9):963-969. PubMed ID: 35081898
[TBL] [Abstract][Full Text] [Related]
10. Placebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes: a pre-specified secondary study on ectopic fat accumulation.
Bizino MB; Jazet IM; de Heer P; van Eyk HJ; Dekkers IA; Rensen PCN; Paiman EHM; Lamb HJ; Smit JW
Diabetologia; 2020 Jan; 63(1):65-74. PubMed ID: 31690988
[TBL] [Abstract][Full Text] [Related]
11. Serum adropin levels are decreased in Chinese type 2 diabetic patients and negatively correlated with body mass index.
Zang H; Jiang F; Cheng X; Xu H; Hu X
Endocr J; 2018 Jul; 65(7):685-691. PubMed ID: 29669965
[TBL] [Abstract][Full Text] [Related]
12. [Associations between serum GDF15 and glycolipid metabolism disorder in metabolic associated fatty liver patients].
Li X; Yu XM; Li EH; Chen PH; Zheng LM; Zhang S
Zhonghua Nei Ke Za Zhi; 2023 Aug; 62(8):987-992. PubMed ID: 37528037
[No Abstract] [Full Text] [Related]
13. Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial.
Guo W; Tian W; Lin L; Xu X
Diabetes Res Clin Pract; 2020 Dec; 170():108487. PubMed ID: 33035599
[TBL] [Abstract][Full Text] [Related]
14. Effect of 5:2 Fasting Diet on Liver Fat Content in Patients with Type 2 Diabetic with Nonalcoholic Fatty Liver Disease.
Xiao Y; Liu Y; Zhao L; Zhou Y
Metab Syndr Relat Disord; 2022 Oct; 20(8):459-465. PubMed ID: 35925752
[No Abstract] [Full Text] [Related]
15. Effect of Liraglutide Therapy on Liver Fat Content in Patients With Inadequately Controlled Type 2 Diabetes: The Lira-NAFLD Study.
Petit JM; Cercueil JP; Loffroy R; Denimal D; Bouillet B; Fourmont C; Chevallier O; Duvillard L; Vergès B
J Clin Endocrinol Metab; 2017 Feb; 102(2):407-415. PubMed ID: 27732328
[TBL] [Abstract][Full Text] [Related]
16. Varied Relationship of Lipid and Lipoprotein Profiles to Liver Fat Content in Phenotypes of Metabolic Associated Fatty Liver Disease.
Wu T; Ye J; Shao C; Li F; Lin Y; Ma Q; Wang W; Feng S; Zhong B
Front Endocrinol (Lausanne); 2021; 12():691556. PubMed ID: 34899591
[TBL] [Abstract][Full Text] [Related]
17. Investigation of adropin and leptin levels in pediatric obesity-related nonalcoholic fatty liver disease.
Sayın O; Tokgöz Y; Arslan N
J Pediatr Endocrinol Metab; 2014 May; 27(5-6):479-84. PubMed ID: 24468600
[TBL] [Abstract][Full Text] [Related]
18. Serum iron is closely associated with metabolic dysfunction-associated fatty liver disease in type 2 diabetes: A real-world study.
Wang JW; Jin CH; Ke JF; Ma YL; Wang YJ; Lu JX; Li MF; Li LX
Front Endocrinol (Lausanne); 2022; 13():942412. PubMed ID: 36133303
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease.
Tian F; Zheng Z; Zhang D; He S; Shen J
Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30473540
[TBL] [Abstract][Full Text] [Related]
20. Regulation of Adropin by Sitagliptin monotherapy in participants with newly diagnosed type 2 Diabetes.
Wang Q; An Y; Zhang L; Zhang Y; Wang G; Liu J
BMC Endocr Disord; 2022 Dec; 22(1):306. PubMed ID: 36476135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
